Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 4/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167219 | 0.92 | PLA2G7 (0.51) | PLA2G7AKR1A1AKR1B1NPC1RAB9A | |
| SCHEMBL4170549 | 0.90 | ALDH1A1 (0.52) | PLA2G7ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL4176442 | 0.85 | AKR1A1 (0.46) | PLA2G7ALDH1A1LMNAMAPTAKR1A1 | |
| SCHEMBL4164829 | 0.84 | AKR1B1 (0.41) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL4169530 | 0.83 | L3MBTL1 (0.42) | ALDH1A1LMNAMAPTPOLBSMN1; SMN2 | |
| SCHEMBL4171124 | 0.82 | AKR1B1 (0.39) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL4262827 | 0.82 | AKR1B1 (0.47) | ALDH1A1MAPTKMT2AAKR1A1AKR1B1 | |
| SCHEMBL4164837 | 0.81 | AKR1B1 (0.48) | MAPTPOLBAKR1A1AKR1B1 | |
| SCHEMBL4166799 | 0.80 | PLA2G7 (0.48) | PLA2G7LMNAPOLBSMN1; SMN2AKR1A1 | |
| SCHEMBL4170928 | 0.80 | AKR1B1 (0.39) | ALDH1A1LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV5, TRPV2 | PLA2G7 2494/4885ALDH1A1 550/4885LMNA 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.